The MOU is a non-binding early-stage collaboration with no financial commitment — it does not change the near-term catalyst path. The key binary event remains the Phase 2 na-SPMS topline data expected in October 2026. Monitor for any subsequent definitive clinical trial agreement or funding announcement from KAIMRC that would convert this MOU into a material partnership.
Price Chart
Executive Summary
Tiziana Life Sciences announced a non-binding MOU with KAIMRC and the Foundation for Neurologic Diseases to collaborate on a clinical trial evaluating intranasal foralumab combined with anti-CD20 therapy in RRMS patients with suboptimal responses to anti-CD20 alone. The MOU is a preliminary collaboration agreement with no financial terms disclosed and does not alter the timeline for the existing Phase 2 na-SPMS trial, which remains blinded with results expected in October 2026.
Key Facts
- MOU signed September 16, 2026 at the Riyadh Global Medical Biotechnology Summit.
- Parties: Tiziana, KAIMRC (King Abdullah International Medical Research Center), and the Foundation for Neurologic Diseases.
- Proposed trial: intranasal foralumab + anti-CD20 therapy in RRMS patients with poor response to anti-CD20 alone.
- No financial terms, funding commitments, or milestone payments disclosed in the MOU.
- Phase 2 na-SPMS trial remains blinded with results expected in October 2026.
- Intranasal foralumab has shown reduced neuroinflammation in three prior clinical studies.
Financial Impact
No financial terms disclosed; non-binding MOU with no committed funding or milestone payments.
Risk Factors
- MOU is non-binding and may not result in a definitive clinical trial agreement.
- No disclosed funding or cost-sharing terms — trial initiation depends on future commitments.
- Combination trial in RRMS is a new indication expansion; regulatory path and enrollment timeline are uncertain.
- Phase 2 na-SPMS data (October 2026) remains the primary value catalyst; any delay or negative read could outweigh the MOU's positive signal.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-100742 |
| Document: ea030581601ex99-1.htm | 0001213900-26-100742 |
| Document: 0001213900-26-100742-index-headers.html | 0001213900-26-100742 |
| Document: 0001213900-26-100742-index.html | 0001213900-26-100742 |
| Document: 0001213900-26-100742.txt | 0001213900-26-100742 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (−11.81%) |
Oct 16, 2026 9d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (+11.81%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8907 (−15.17%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8907 (−19.76%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 | awaiting T+20 | — | $0.8907 (−9.11%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8907 (−1.54%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8907 (−22.55%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8907 (−8.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers